We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The drug pricing debate is raging on in Washington, D.C., and that's part of the reason Bristol-Myers Squibb wants to nab Celgene, CEO Giovanni Caforio told analysts Thursday.